Lipid changes in patients receiving nevirapine (NVP) in combination with tenofovir/emtricitabine: results from the CCIAT trial
© Davis et al; licensee BioMed Central Ltd. 2008
Published: 10 November 2008
Highly effective antiretroviral (ARV) therapy has resulted in improved patient (pt) longevity, but many ARV regimens are associated with increases in blood lipid markers, raising concern with the potential for premature atherosclerosis and coronary artery disease. Prior studies with NVP in ARV-naïve pts noted an increase in low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs), although less significant than the high-density lipoprotein cholesterol (HDL-C) increase. The contribution of the NRTI backbone to this effect was unclear.
To address this, 39 pts were randomly chosen to participate in a lipid substudy of the Cell Cycle Independent ARV Therapy (CCIAT) trial; pts (N = 54: 67% men, 95% African-American) received NVP 200 mg twice daily in combination with once-daily tenofovir/emtricitabine (TDF/FTC) 300/200 mg in this trial which was designed to investigate the efficacy and safety of this regimen.
Summary of results
The combination of NVP plus TDF/FTC resulted in apparent positive effects on serum lipids, with an increase in HDL-C, decrease in TGs and little change in LDL-C and TC. This regimen might improve the cardiovascular risk profile of pts taking ARV therapy.
This article is published under license to BioMed Central Ltd.